Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Profit After Tax (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Profit After Tax over the past 3 years, most recently at -$46.9 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$46.9 million for Q4 2025, down 106.26% from a year ago — trailing twelve months through Dec 2025 was -$122.2 million (up 10.98% YoY), and the annual figure for FY2025 was -$121.6 million, up 11.8%.
  • Profit After Tax for Q4 2025 was -$46.9 million at Tonix Pharmaceuticals Holding, down from -$31.8 million in the prior quarter.
  • Over the last five years, Profit After Tax for TNXP hit a ceiling of -$15.8 million in Q3 2024 and a floor of -$77.3 million in Q2 2024.
  • Median Profit After Tax over the past 3 years was -$27.7 million (2023), compared with a mean of -$31.3 million.
  • Biggest five-year swings in Profit After Tax: plummeted 172.66% in 2024 and later skyrocketed 64.62% in 2025.
  • Tonix Pharmaceuticals Holding's Profit After Tax stood at -$27.3 million in 2023, then increased by 16.7% to -$22.8 million in 2024, then tumbled by 106.26% to -$46.9 million in 2025.
  • The last three reported values for Profit After Tax were -$46.9 million (Q4 2025), -$31.8 million (Q3 2025), and -$27.4 million (Q2 2025) per Business Quant data.